Skip to main content

Pharmacy

By Kaiser Health News | 08:55 am | October 03, 2016
Since the medicine generally expires every year, the cost to replace EpiPens adds up fairly quickly, especially for consumers who do not have insurance or have high-deductible plans.
By Kaiser Health News | 08:34 am | October 03, 2016
Naltrexone and acamprosate are the two drugs on the market for patients with alcohol cravings.
By Kaiser Health News | 11:37 am | September 30, 2016
The ticket, known as a rare pediatric disease priority review voucher, is part of a program created by Congress in 2007 to encourage the development of drugs for tropical diseases and later expanded to rare pediatric disorders.
By Kaiser Health News | 10:21 am | September 29, 2016
Views come as the skyrocketing prices of some drugs are under intense scrutiny, with new evidence showing massive price hikes by some companies.
By Jeff Lagasse | 01:54 pm | September 21, 2016
Gradual price hikes, growth in users pushes up spending for the federal prescription drug program.
By Kaiser Health News | 02:06 pm | September 20, 2016
The first drug to treat Duchenne muscular dystrophy could sell for $350,000 a year.
By Jeff Lagasse | 09:31 am | September 20, 2016
HHS says at least 2 million people become infected with antibiotic-resistant bacteria, with 23,000 dying as a result.
By Jessica Davis | 09:14 am | September 13, 2016
Israel-based pharmaceutical company will meet with U.S. FDA to re-submit its marketing application, hopes to launch generic by 2018.
By Kaiser Health News | 08:40 am | September 13, 2016
From 2011 to 2015, insurers' payments to hospitals, laboratories, treatment centers and other medical providers for these patients grew from $32 million to $446 million -- a 1,375 percent increase.
By Kaiser Health News | 11:08 am | September 09, 2016
Consumers Union wants to know why the cost projections submitted by Anthem and Blue Shield are so much higher than some of their competitors and other industry-wide figures.